Gilead Sciences director Jeffrey Bluestone sells $725,077 in stock

Gilead Sciences director Jeffrey Bluestone sold $725,077 worth of the company's common stock on August 20, 2026. The sales occurred at prices between $143.75 and $146.36 per share, with the stock currently trading at $146.15, close to its 52-week peak of $157.29. The transactions included option exercises worth approximately $335,206, acquired at prices ranging from $61.35 to $67.45.

Bluestone exercised options for 5,000 shares, later selling an equal amount. Gilead Sciences is perceived as overvalued according to InvestingPro analysis. The director now holds 10,066 shares of the company. Gilead reported strong Q2 2026 earnings, beating analyst forecasts, while its stock saw a modest decline in after-hours trading.

The company also exercised an option for a MacroGenics preclinical bispecific program, resulting in a $10 million payment. Morgan Stanley's recent analysis highlighted a 1.5% increase in total prescriptions in the U.S. prescription drug market.